Background: The thromboembolic events are considered a potentially serious complication in the bariatric surgery patients. Rivaroxaban has been investigated in bariatric surgery patients in few studies. More evidence on whether the postsurgical anatomical and the physiological changes effect rivaroxaban pharmacokinetics need to be identified. Objective: The aim of this study is to investigate the pharmacokinetics parameters of rivaroxaban in obese patients undergoing bariatric surgery. Methods: The study includes 20 obese patients who were admitted for bariatric surgery and intended to receive prophylaxis doses of Rivaroxaban. High-performance liquid chromatography (HPLC) was used to determine pre and postoperative rivaroxaban plasma concentration. This study assessed the participants' efficacy and safety of rivaroxaban by following up these outcomes 6 and 9 months after the surgery. Results: Twenty patients were included in the study of which 40% are male. The average age was 33.9 ± 10 years and the mean body weight was 117.6 ± 21.2 kg. The average maximum concentrations (Cmax) were 0.31 ± 0.1 μg/ml, 0.23 ± 0.12 μg/ml, and 0.28 ± 0.1 in pre- and post-surgery and 7 days after bariatric surgery, respectively. There was no statistical significance between the measured levels of rivaroxaban. No significant bleeding events,or other side effects which others ???associated with rivaroxaban medication were reported during the trial period. In addition, no DVT or PE events were reported over 6,9 months Conclusions: Rivaroxaban shows promise as a potential medication for VTE prophylaxis after bariatric surgery. However, more research is needed to determine its optimal dosage and long-term safety profile in this patient population. Keywords: anticoagulants; bariatric surgery; rivaroxaban; thromboprophylaxis.
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal